Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | HINT1 | P49773 | 3/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636462 | 0.89 | ADORA2A (0.51) | HPGDADORA2AADORA3HINT1NT5E | |
| SCHEMBL31225342 | 0.89 | ADORA2A (0.51) | HPGDADORA2AADORA3HINT1NT5E | |
| SCHEMBL19352193 | 0.87 | ADORA3 (0.50) | HPGDADORA2AADORA3HINT1NT5E | |
| SCHEMBL14594720 | 0.87 | ADORA3 (0.50) | HPGDADORA2AADORA3HINT1NT5E | |
| SCHEMBL20250995 | 0.87 | ADORA2A (0.53) | HPGDADORA2AADORA3HINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL14853673 | 0.86 | ADORA2A (0.65) | HPGDADORA2AADORA3HINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL14842089 | 0.86 | ADORA2A (0.65) | HPGDADORA2AADORA3HINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL12149502 | 0.86 | ADORA2A (0.65) | HPGDADORA2AADORA3HINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL12758165 | 0.86 | ADORA2A (0.65) | HPGDADORA2AADORA3HINT1NT5E | |
| 2'-B-Methyl-Guanosine SCHEMBL21007207 | 0.86 | ADORA2A (0.65) | HPGDADORA2AADORA3HINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176018-A1 | Chemically modified double stranded nucleic acid molecules | SIRNA THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6673611-B2 | ENHANCED NUCLEASE RESISTANCE, BINDING AFFINITY, AND/OR POTENCY | SIRNA THERAPEUTICS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020142980-A1 | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | RIBOZYME PHARMACEUTICALS INC. | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142980-A1 | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | NSUN2, RNMT, NSUN3 | HPGD 3520/4885ADORA2A 890/4885ADORA3 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.